Increased Competitive Pressure in Antiepileptic Market Following Topiramate Submission
Neurology · Antiepileptic • Pipeline Update • Jun 19, 2026
Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The submission of ANDA078499 for Topiramate by Aiping Pharm Inc. signifies an impending increase in competition within the antiepileptic market. This could lead to shifts in pricing strategies and market dynamics that pharma companies must proactively manage. Regulatory context from FDA (FDA AP — TOPIRAMATE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (13 high-relevance).
Strategic Assessment
Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies for Topiramate. The strongest clinical anchor is A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Neurology · Antiepileptic, 8 regulatory and 4 competitive items passed relevance filtering for Topiramate.
Competitive Pressure
The most relevant competitive pressure comes from ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis (Humanexa Signals) — entity match (neurology). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This submission indicates Aiping Pharm Inc.'s intent to enter the market for Topiramate, potentially increasing competition in the antiepileptic drug space.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — TOPIRAMATE (SUPPL) (FDA). Entity match (topiramate); Regulatory pathway relevance (nda). The submission has a standard review priority, indicating that while it is being evaluated, it is not expected to face significant regulatory hurdles.
Key Risks
- Competitive pressure on Topiramate: This submission indicates Aiping Pharm Inc.'s intent to enter the market for Topiramate, potentially increasing competit.
Key Opportunities
- Increased competition may pressure pricing and market share for existing Topiramate products, impacting revenue streams for current manufacturers.
- Upside for Topiramate may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
- Upside for Topiramate may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
- Upside for Topiramate may improve if Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (ClinicalTrials.gov) delivers favorable follow-through.
- Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies for Topiramate.
What Would Change This Assessment
- This becomes more urgent if Monitor the review progress of ANDA078499 and any subsequent approvals or market entries by Aiping Pharm Inc.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceMultimorbidity and Polypharmacy in People With HIV vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEvaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTrial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceSingle Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceComparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
No evidence in this category.
Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePotential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceComparison of Transumbilical Single‑Port and Multi‑Port Laparoscopic Myomectomy in Patients with Uterine Fibroids: Effects on Stress Response, Immune Function, and Incision Cosmetic Outcomes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceLavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceImmune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Related Signals
- FDA Submission Update for Topiramate by Aiping Pharm Inc.
Pipeline Update
Related Regulatory Precedents
FDA
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
Application ANDA208175. Sponsor: DR REDDYS LABS SA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PHENTERMINE HYDROCHLORIDE, TOPIRAMATE.
SourceFDA
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
Application ANDA204982. Sponsor: ACTAVIS LABS FL INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PHENTERMINE HYDROCHLORIDE, TOPIRAMATE.
SourceFDA
FDA AP — TOPIRAMATE (SUPPL)
Application ANDA079162. Sponsor: INVAGEN PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TOPIRAMATE.
SourceFDA
FDA AP — TOPIRAMATE (SUPPL)
Application ANDA079162. Sponsor: INVAGEN PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TOPIRAMATE.
SourceFDA
FDA AP — TOPIRAMATE (ORIG)
Application ANDA220041. Sponsor: RICONPHARMA LLC. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TOPIRAMATE.
Source